In recent years, the status of the API industry has continued to rise. It has evolved from a basic supporting link in the upstream of the pharmaceutical industrial chain into a core pillar of the pharmaceutical supply chain, a critical source for formulation quality, and a key
segment driving industrial value enhancement.
At the policy level, the implementation of associated review and approval, alignment with ICH international guidelines, and the normalization of volume-based procurement have forged an in-depth bond between APIs and pharmaceutical formulations. The compliance threshold has been raised substantially, accelerating the industry's survival of the fittest and driving a steady increase in industrial concentration among leading enterprises.
At the market level, the mass expiration of global patented drugs has driven a sharp growth in demand for specialty APIs. Domestic enterprises are gradually shifting from low-end competition in bulk APIs to high-barrier specialty APIs, patented APIs and integrated CDMO services, with a remarkable expansion of profit margins.
Meanwhile, the overseas expansion of innovative drugs and generic drugs has accelerated. Cutting-edge pharmaceuticals such as peptides and high-end small-molecule drugs have become increasingly reliant on high-quality APIs. Supported by the drive for supply chain independence and controllability, green production as well as the iteration of new processes, the strategic value of the API industry has been further highlighted. High-end development, integration and internationalization will become the mainstream development trends of the industry in the future.
